DaVita (NYSE:DVA) Cut to “Hold” at Zacks Research

Zacks Research cut shares of DaVita (NYSE:DVA) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports.

DVA has been the subject of several other reports. UBS Group raised their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Barclays raised their target price on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 target price on shares of DaVita in a research note on Thursday, February 5th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $155.80.

DaVita Price Performance

Shares of DVA opened at $148.52 on Monday. DaVita has a one year low of $101.00 and a one year high of $159.42. The company has a 50-day simple moving average of $147.22 and a two-hundred day simple moving average of $129.19. The firm has a market capitalization of $9.92 billion, a PE ratio of 14.99, a price-to-earnings-growth ratio of 0.51 and a beta of 0.92.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business had revenue of $3.62 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same period last year, the business posted $2.24 earnings per share. DaVita’s quarterly revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Analysts expect that DaVita will post 10.76 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

A number of hedge funds have recently added to or reduced their stakes in DVA. Hsbc Holdings PLC increased its stake in shares of DaVita by 71.7% in the 4th quarter. Hsbc Holdings PLC now owns 133,080 shares of the company’s stock worth $15,110,000 after purchasing an additional 55,553 shares in the last quarter. Rockefeller Capital Management L.P. boosted its holdings in DaVita by 26.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,049 shares of the company’s stock worth $119,000 after buying an additional 221 shares during the period. Corient Private Wealth LLC boosted its holdings in DaVita by 22.5% in the 4th quarter. Corient Private Wealth LLC now owns 27,559 shares of the company’s stock worth $3,131,000 after buying an additional 5,069 shares during the period. Sankala Group LLC bought a new position in DaVita in the 4th quarter worth $39,000. Finally, Virtu Financial LLC bought a new position in shares of DaVita during the 4th quarter valued at about $451,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.